Natco Pharma (BOM:524816) Debt-to-EBITDA : 0.17 (As of Mar. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Natco Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Natco Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹3,659 Mil. Natco Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹53 Mil. Natco Pharma's annualized EBITDA for the quarter that ended in Mar. 2024 was ₹21,572 Mil. Natco Pharma's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Natco Pharma's Debt-to-EBITDA or its related term are showing as below:

BOM:524816' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.15 Med: 0.42 Max: 1.51
Current: 0.15

During the past 13 years, the highest Debt-to-EBITDA Ratio of Natco Pharma was 1.51. The lowest was 0.15. And the median was 0.42.

BOM:524816's Debt-to-EBITDA is ranked better than
84.42% of 661 companies
in the Drug Manufacturers industry
Industry Median: 1.7 vs BOM:524816: 0.15

Natco Pharma Debt-to-EBITDA Historical Data

The historical data trend for Natco Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Natco Pharma Debt-to-EBITDA Chart

Natco Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-EBITDA

Get a 7-Day Free Trial

0.48

0.40

1.21

0.17

0.20

Natco Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial															0.12	-	0.13	-	0.17

Competitive Comparison of Natco Pharma's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Natco Pharma's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Natco Pharma's Debt-to-EBITDA falls into.

Natco Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Natco Pharma's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(3659	+	53)	/	18795
	=	0.20

Natco Pharma's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(3659	+	53)	/	21572
	=	0.17

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Natco Pharma (BOM:524816) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Natco Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Natco Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Natco Pharma (BOM:524816) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Natco Pharma Ltd (BOM:524816) » Definitions » Debt-to-EBITDA

Traded in Other Exchanges

NATCOPHARM:India

Address

Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034

Website

https://www.natcopharma.co.in

Natco Pharma Ltd is a major drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. Within the pharma business segment, the company drives its sales through Finished Dosage Forms and Active Pharmaceutical Ingredients.

Natco Pharma (BOM:524816) Headlines

No Headlines